Early data indicates Moderna's COVID-19 vaccine is highly effective in adolescents between the ages of 12 and 17, the company says.
Moderna released this data on Thursday along with its first-quarter earnings, CNBC reported. An initial analysis of a study of its COVID-19 vaccine in adolescents between 12 and 17 years old "showed a vaccine efficacy rate of 96 percent," the company said. The vaccine was also "generally well tolerated," and the "majority of adverse events were mild or moderate in severity." Like Pfizer, Moderna also said Thursday it plans to apply for full FDA approval of the vaccine this month.
The Food and Drug Administration is reportedly on the verge of authorizing the Pfizer-BioNTech COVID-19 vaccine for children between 12 and 15 years old, allowing the vaccine to expand to this key age group ahead of the next school year. In March, Pfizer said a trial showed its vaccine was 100 percent effective in adolescents aged 12 to 15, demonstrating "robust antibody responses." President Biden earlier this week said his administration's COVID-19 vaccination efforts are set to enter a "new phase," which includes vaccinating kids between 12 and 15 pending FDA approval of the Pfizer vaccine.
Meanwhile, Pfizer has also said it expects to seek authorization of its vaccine for kids between 2 and 11 this September, and Moderna says a phase 2 study of its vaccine in children 6 months to 11 years old is ongoing.